Phase III KEYNOTE-A18 trial meets primary endpoint of PFS in cervical cancer

One-tube test could expand cervical cancer screening, speed diagnosis

Harnessing the power of CRISPR gene-editing technology in a new way, University of Florida researchers have created a one-tube testing method targeting DNA from body fluids that has the potential to dramatically increase access to the diagnosis of viral diseases such as cervical cancer.

May 03, 2024

Vol.50 No.18

In Brief

LSU LCMC Health research team granted $1.2M to address barriers to cervical cancer prevention

A research team from Louisiana State University LCMC Health Cancer Center has been awarded a $1.5 million grant to eliminate barriers from cervical cancer prevention.

January 26, 2024

Vol.50 No.04

Drugs & Targets

FDA approves Keytruda + chemoradiotherapy for FIGO 2014 stage 3-4A cervical cancer

FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.

January 19, 2024

Vol.50 No.03

Drugs & Targets

FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer

FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for Keytruda (pembrolizumab) in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk, locally advanced cervical cancer.

September 22, 2023

Vol.49 No.35

As U.S. courts, politicians take aim at preventive care, cervical cancer screening declines, HPV vaccine uptake stays uneven

In an era of intensifying judicial repudiation of evidence-based guidelines and deepening public mistrust toward science, America’s screening rate for cervical cancer has been declining.

July 21, 2023

Vol.49 No.29

By Matthew Bin Han Ong

Conversation with The Cancer Letter

St. Jude’s Heather Brandt: NCI cancer centers must leverage community trust to boost HPV vaccine uptake in children

St. Jude’s Path to a Bright Future, an HPV awareness and vaccination campaign with nearly 160 partners, is aimed at reducing that disease burden by targeting children in a crucial age range.